TSX: TMC
TORONTO, Nov. 29 /PRNewswire-FirstCall/ -- Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), an emerging leader in the commercial genetic testing market, today announced that it has signed a distribution agreement with Gamidor Diagnostics (Petach Tikva, Israel), a leading distributor of clinical diagnostics in Israel. Under the agreement, Gamidor will have exclusive rights to distribute the Tag-It(TM) menu of genetic tests in Israel for a minimum three-year term that can be extended annually. As Tm launches new products, they can be rolled in to the agreement upon approval of both parties.
"Gamidor, like Tm, is committed to providing its customers with the most advanced and accurate diagnostic technology available," said Greg Hines, President and CEO of Tm Bioscience. "They are the ideal partners to enable Tm to penetrate a major market for our products beyond North America."
Gamidor distributes products in Israel for the world's largest suppliers of clinical diagnostics, including Perkin Elmer Life Sciences and Dade Behring.
"The market for genetic tests is well established in Israel and we anticipate tests from Tm, in particular their Cystic Fibrosis gene test and Ashkenazi Jewish Panel, will be well received," said Yacob Ofer, CEO of Gamidor Diagnostics. "These will be important products to showcase Gamidor's leadership role as a provider of cutting edge diagnostic products."
About Gamidor Diagnostics
The mission of Gamidor Diagnostics is to provide systems, chemicals, reagents and services to clinical and research laboratories in Israel. Gamidor Diagnostics is marketing and customer orientated. It employs a highly motivated and dedicated group of people (30), who understand the customer needs and have the qualifications and experience required to service them.
About Tag-It(TM) genetic tests
Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has already commercialized a series of Tag-It(TM) tests for coagulation genes (Factor V, Factor II, MTHFR)(x), Cystic Fibrosis gene (CFTR 40+4 and ASR format)(xx), and drug metabolism genes (Tag-It(TM) P450-2D6, P450-2C9, P450-2C19)(x). All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a well established bead based instrument. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, highly accurate, high-throughput, low-cost DNA-based tests.
(x) For Research Use Only. Not for use in diagnostic procedures.
(xx) Analyte Specific Reagent. Analytical and performance characteristics
are not established.
About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic disorders, drug metabolism, and infectious diseases. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Quelle: TM Bioscience
